文献速递血液净化与透析

血液透析患者中SARS-CoV-2特异性T细胞反应与再感染保护无关

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.
PubMed 文献 · J Am Soc Nephrol · 2022-03-31

研究报道未接种疫苗的血液透析患者再感染发生率高达25%,再感染者初次感染期间对多种SARS-CoV-2肽池表现出高度可变且有时强烈的增殖性T细胞反应,表明T细胞反应不能预测再感染保护。

要点

  • 未接种疫苗的血液透析患者再感染发生率为25%。
  • 再感染者初次感染时T细胞反应高度可变,有时强烈。
  • SARS-CoV-2特异性T细胞反应不能预测再感染保护。

核心结论

  • 血液透析患者中SARS-CoV-2特异性T细胞反应不能预测对再感染的保护。

研究设计与样本

  • 研究报道未接种疫苗的血液透析患者队列中再感染发生率为25%。

主要发现

  • 未接种疫苗的血液透析患者再感染发生率为25%。
  • 再感染者初次感染期间对广泛SARS-CoV-2肽池表现出高度可变且有时强烈的增殖性T细胞反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients on hemodialysis (HD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mount poor neutralizing antibody responses after two-dose vaccination. Although serological responses have been associated with reduced rates of reinfection, the relationship between cellular immunogenicity and protection has not been established. We report, for the first time, high incidence of reinfection in patients on HD who are vaccine naive (25%), which identifies that T cell responses do not predict protection against reinfection. Instead, patients on HD who went on to become reinfected had mounted highly variable and sometimes robust proliferative T cell responses to a broad array of SARS-CoV-2 peptide pools during the primary infection. The understanding that SARS-CoV-2–specific T cell responses are not predictive of protection against future infection will be a critical issue when measuring clinical efficacy of vaccination in these vulnerable cohorts, particularly when facing rapidly emerging variants of concern.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Shankar S, Beckett J, Tipton T, et al. SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. J Am Soc Nephrol. 2022. PMID: 35361708. doi:10.1681/ASN.2021121587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。